key: cord-0735566-mpikm299
authors: Kurra, Nithin; Woodard, Priyanka Isaac; Gandrakota, Nikhila; Gandhi, Heli; Polisetty, Srinivasa Rao; Ang, Song Peng; Patel, Kinjalben P; Chitimalla, Vishwaj; Ali Baig, Mirza M; Samudrala, Gayathri
title: Opportunistic Infections in COVID-19: A Systematic Review and Meta-Analysis
date: 2022-03-31
journal: Cureus
DOI: 10.7759/cureus.23687
sha: 4777e28ee20b8a708c37ac29ea4dec3be7a3f587
doc_id: 735566
cord_uid: mpikm299

The prevalence, incidence, and characteristics of bacterial infections in patients infected with severe acute respiratory syndrome coronavirus 2 are not well understood and have been raised as an important knowledge gap. Therefore, our study focused on the most common opportunistic infections/secondary infections/superinfections in coronavirus disease 2019 (COVID-19) patients. This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Eligible studies were identified using PubMed/Medline since inception to June 25, 2021. Studies meeting the inclusion criteria were selected. Statistical analysis was conducted in Review Manager 5.4.1. A random-effect model was used when heterogeneity was seen to pool the studies, and the result was reported as inverse variance and the corresponding 95% confidence interval. We screened 701 articles comprising 22 cohort studies which were included for analysis. The pooled prevalence of opportunistic infections/secondary infections/superinfections was 16% in COVID-19 patients. The highest prevalence of secondary infections was observed among viruses at 33%, followed by bacteria at 16%, fungi at 6%, and 25% among the miscellaneous group/wrong outcome. Opportunistic infections are more prevalent in critically ill patients. The isolated pathogens included Epstein-Barr virus, Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Hemophilus influenza, and invasive pulmonary aspergillosis. Large-scale studies are required to better identify opportunistic/secondary/superinfections in COVID-19 patients.

The coronavirus disease 2019 (COVID- 19) pandemic has been associated with fatal outcomes. Recent studies have shown that the primary route of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is through respiratory droplets [1, 2] . Studies have also shown that 25% of older individuals affected with influenza acquire secondary bacterial infections [3, 4] . Moreover, these individuals have been reported to have superinfections and coinfections with SARS-CoV-2 [5] [6] [7] . However, there is limited data on the frequency of viral, bacterial, or fungal coinfections and superinfections in COVID-19 patients [5] [6] [7] .

This systematic review and meta-analysis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [10] . We searched data from PubMed/Medline from their inception to June 25, 2021, using the following keywords: "bacterial infections AND covid," "coinfections AND covid," "fungal infections AND covid," "opportunistic infections AND covid," "opportunistic pulmonary AND covid," "secondary infections AND covid," "superinfections AND covid." We also screened review articles, cohort studies, randomized controlled trials (RCTs), and meta-analyses for further relevance.

Our eligibility criteria for the studies, abbreviated as PECOS, included the following: 

Statistical analysis was done using the Review Manager (version 5.4.1; The Nordic Cochrane Centre, Copenhagen) and the Cochrane Collaboration tool. We pooled the data from studies using a random-effects model when heterogeneity was present. We analyzed the results by calculating the inverse variance (IV) with respective 95% confidence intervals (CIs). Any differences between the subgroups were determined using the chi-square test. We performed a sensitivity analysis to look for any single study that could be driving the results and to assess the cause of high heterogeneity. I 2 is the degree of inconsistency measured (range: 0-100%) across studies in a meta-analysis. It quantifies the effect of heterogeneity rather than chance. Heterogeneity scales were considered as follows based on the Cochrane handbook: I 2 = 25-60%, moderate; 50-90%, substantial; 75-100%, considerable heterogeneity. Pvalues of <0.1 indicated significant heterogeneity [11] . P-values of <0.05 were considered significant for all analyses.

Prevalence was calculated using raw data. This along with other extracted information was used to find standard errors using the formula:

Where p is the prevalence and n is the number of COVID-19 patients. The prevalence and standard error of each study were then entered into the Review Manager through the IV method to compute pooled prevalence along with 95% CIs.

We searched the electronic databases, exported the studies to the EndNote Reference Library software, version 20.0.1 (Clarivate Analytics), and removed any duplicates after screening. We extracted the data and assessed the quality of the cohort studies using the Newcastle-Ottawa Scale (NOS) where a score of 1-5 was considered high risk for bias, 6-7 as moderate, and >7 as low ( 

Approximately 701 studies were searched initially from the electronic databases. There were no duplicates. We excluded 30 articles based on their title and abstracts. The full texts from 311 studies were examined to be included after excluding studies based on titles and abstracts. Finally, 22 studies were included in the quantitative analysis. Figure 1 shows our literature search results. Table 2 provides the basic characteristics of included studies. In total, 22 studies included a total of 13,550 patients . Overall, 13 studies were from Europe [15] [16] [17] [18] [19] [20] 22, 23, [25] [26] [27] 29, 30] , five were from Asia [12, 14, 21, 28, 31] , two were from the United States [32, 33] , one was from Russia [13] , and one was from Mexico [24] . Two studies were part of the bacteria, virus, and fungi group [15, 18] ; one was part of bacteria and fungi only [16] ; four were part of the bacteria-only group [12] [13] [14] 17] ; eight were part of the fungi-only group [19] [20] [21] [22] [23] [24] [25] [26] ; one was in the virus-only group [27] , and six were in the miscellaneous group [28] [29] [30] [31] [32] [33] . Table 2 highlights the prevalence of death within these studies. Most deaths were reported by Sharifipour et al., while the majority of other studies with a larger population size had a mortality rate between 10% and 40% [12] .

A funnel plot showing asymmetry which suggests publication bias is shown in Figure 2 . Overall, three studies had a moderate risk of bias [12, 19, 24] while 19 studies had a low risk of bias [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] [31] [32] [33] .

The pooled prevalence of opportunistic infections/secondary infections/superinfections in COVID-19

patients was 16% (95% CI = 14-19%; I 2 = 99%) ( Figure 3) . Our study showed the highest prevalence of secondary infections among viruses at 33% (95% CI = 3-62%), while it was 16% (95% CI = 9-23%) among the bacteria subgroup, 6% (95% CI = 4-8%) among the fungi subgroup, and 25% (95% CI = 17-34%) among the miscellaneous group/wrong outcome. Most studies showed significant results, but few studies showed nonsignificant results. Sharifipour et al. [12] in the bacteria subgroup; Garcia-Vidal, et al. [15] , Bayram et al. [22] , Søgaard et al. [18] , and Gouzien et al. [26] in the fungi subgroup; and Garcia-Vidal et al. [15] and Søgaard et al. [18] in the virus subgroup showed non-significant prevalence. All studies in the miscellaneous subgroup were statistically significant. The overall heterogeneity was significantly high (I 2 = 99%, p < 0.00001). The reason for such high heterogeneity might be the pooling of studies with different organisms; however, because we did not want to stratify our results based on the species rather than on the class of organism, this high heterogeneity did not affect our analysis.

A sensitivity analysis was performed to determine the influence of each study on the overall effect. We excluded one study at a time, followed by the generation of pooled prevalence for the remaining studies. There was no significant effect of any study on the indicated robust results.

In this systematic review and meta-analysis, we determined the prevalence of opportunistic infections in COVID-19 patients. The analysis showed the highest prevalence of viruses in COVID-19 patients, followed by bacteria and fungi. While screening articles for this study, interesting data were revealed by various studies on secondary infections and superinfections in COVID-19 patients.

In a study by Paolucci et al., a correlation between EBV load and COVID-19 severity was observed [27] . Razazi et al. in a retrospective study compared the incidence of ventilator-associated pneumonia (VAP) and invasive aspergillosis among individuals with COVID-19-associated acute respiratory distress syndrome (C-ARDS) and those with non-SARS-CoV-2 viral ARDS (NC-ARDS) [19] . They evaluated mechanically ventilated 90 C-ARDS and 82 NC-ARDS patients. There were substantially fewer bacterial coinfections in the C-ARDS than in the NC-ARDS group: 14 (16%) versus 38 (48%) (p < 0.01) at the time of ICU admission. On the contrary, more patients suffered at least one episode of VAP in the C-ARDS group compared to the NC-ARDS: 58 (64%) versus 36 (44%) (p = 0.007). The probability of VAP was high in the C-ARDS group postmortality adjustment and removal of the ventilator (sub-hazard ratio = 1.72 (1.14-2.52), p < 0.01). The C-ARDS group had a higher incidence of multidrug-resistant bacteria (MDR)-related VAP than the NC-ARDS group: 21 (23%) versus 9 (11%) (p = 0.03). The C-ARDS group received more carbapenem compared to NC-ARDS: 48 (53%) versus 21 (26%) (p < 0.01).

White et al. in their prospective cohort study determined the incidence, risk factors, and impact of invasive fungal infections in adult COVID-19 patients with severe respiratory distress [20] . Out of 135 COVID-19positive individuals (with a median age of 57 and a male-to-female ratio of 2·2/1), 26.7% (14.1% aspergillosis, 12.6% yeast infections) were reported. The mortality rate was 38%; 53% in patients with fungal diseases and 31% in patients without fungal diseases (p = 0.0387). Antifungal treatment declined the mortality rate (38.5% in patients receiving therapy versus 90% in patients not receiving therapy; p = 0.008). The tendency of aspergillosis was increased with corticosteroids (p = 0.007) and medical history of chronic respiratory disease (p = 0.05). A fungal disease was observed often in critically ill COVID-19 patients. [26] .

Based on the literature evidence, superinfections and respiratory coinfections in SARS-CoV-2-positive patients were more prevalent in critically ill COVID-19 patients. Among patient characteristics, a significant relationship was found in men with COVID-19. In their study, Paolucci et al. supported the correlation between lymphopenia and increased viral load (especially EBV), which shows the relationship between immunosuppression and viral prevalence [27] . Several studies [17, 19, 20] have reported increasing bacterial superinfections which could be due to antibiotic resistance, further warranting optimum ways to monitor antibiotic usage.

Our study has certain limitations. COVID-19 is a novel disease, and its relationship between pathophysiology and patient presentation is not well understood. We examined COVID-19 patients with superinfections or opportunistic infections, and the occurrence of these infections in COVID-19 patients may not be correctly identified as there were no consistent screening tools used to identify these infections.

Opportunistic infections are more prevalent in critically ill patients. The isolated pathogens included EBV, Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Hemophilus influenzae, and invasive pulmonary aspergillosis. Large-scale studies are required to estimate opportunistic/secondary/superinfections in COVID-19 patients.

In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Bacterial coinfection in influenza: a grand rounds review

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients

Paniz Mondolfi AE: Coinfection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus?

Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan . medRxiv. 2020

Opportunistic infections--coming to the limits of immunosuppression

Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and metaanalysis

The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations

Measuring inconsistency in meta-analyses

Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU

SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: secondary bacterial pneumonia and viral co-infections

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia

Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease

A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit

Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations

Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: results from the prospective AspCOVID-19 study

COVID-19-associated invasive pulmonary aspergillosis in a tertiary care center in Mexico City

Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia

Invasive Aspergillosis associated with Covid-19: a word of caution

EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count

Risks and features of secondary infections in severe and critical ill COVID-19 patients

Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome

Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study

Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance

Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections

Predictors and outcomes of healthcare-associated infections in COVID-19 patients